Our Solution

Market Opportunity

Market Opportunity

Market Opportunity

The Market Opportunity


Market demand is growing rapidly as Millennials and Gen Z, now major pet owners, drive pet humanization and demand for advanced care, with pet insurance seeing significant growth now covering cancer therapy. However, pet parents face very limited treatment options relying on toxic, outdated chemotherapies as veterinary oncology remains decades behind human medicine. This vast unmet need, combined with growing One Health investment, creates the right timing for introducing safer, more effective therapy solutions to life-threatening disease in companion animals.

Market demand is growing rapidly as Millennials and Gen Z, now major pet owners, drive pet humanization and demand for advanced care, with pet insurance seeing significant growth now covering cancer therapy. However, pet parents face very limited treatment options relying on toxic, outdated chemotherapies as veterinary oncology remains decades behind human medicine. This vast unmet need, combined with growing One Health investment, creates the right timing for introducing safer, more effective therapy solutions to life-threatening disease in companion animals.

Market demand is growing rapidly as Millennials and Gen Z, now major pet owners, drive pet humanization and demand for advanced care, with pet insurance seeing significant growth now covering cancer therapy. However, pet parents face very limited treatment options relying on toxic, outdated chemotherapies as veterinary oncology remains decades behind human medicine. This vast unmet need, combined with growing One Health investment, creates the right timing for introducing safer, more effective therapy solutions to life-threatening disease in companion animals.

  • Over 200 million dogs & 200 million cats living in Europe and US, have guardians increasingly see them as family.

  • Number of pets insured have increased more than 3-fold in the last 7 years.

  • The global veterinary medicine market was estimated at $50 billion in 2024 and is expected to grow to $80 billion by 2030.

Our Solution

Our Solution

Our Solution

Our First Breakthrough Therapy


Nebumet is an off-the-shelf nebulized immunotherapy that treats and prevents lung metastases in dogs with solid tumors. Our proprietary formulation of the proven BCG vaccine is delivered directly to the lungs where cancer often spreads, extending survival while maintaining quality of life. With multiple patent protections through 2045 and a clear regulatory pathway, Nebumet offers a compelling investment opportunity.


  • Novel delivery of established immunotherapy with >30 years of human safety data

  • Shown great potential already in improvement of survival time in dogs

  • First veterinary market approval expected 2028

Silhouette of a researcher examining a slide under a microscope with a blue background.
Silhouette of a researcher examining a slide under a microscope with a blue background.
Silhouette of a researcher examining a slide under a microscope with a blue background.

Science

Science

Science

The Scientific Foundation

Our comparative oncology approach recognizes that canine cancers mirror human disease, offering valuable insights for treatments across species. Nebumet works by triggering local immune activation in the lungs to combat metastatic cancer cells, addressing a critical weakness in current treatment protocols. Our technology is backed by safety and efficacy evidence across multiple species and targets the most lethal aspect of cancer—metastasis.

  • Robust in vivo evidence across multiple species supports efficacy

  • Mechanism activates the body's immune system against cancer cells

  • Platform technology expandable to multiple cancer types and species

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Alv B create value for our shareholders.

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Alv B create value for our shareholders.

Today Dogs, Tomorrow Humans.

Through development of new treatment methods, research and data products will Alv B create value for our shareholders.

Alv B AS is a Norwegian biotech company that develops cutting-edge, cost-effective cancer treatments for dogs. We benefit from a forward-thinking team well-versed in the latest advances in cancer research on humans, as well as dogs.

Alv B AS Copyright 2025 © All Right Reserved.

Alv B AS is a registered company in Norway (Org.nr. 924 846 208). The company is authorized under the Norwegian Medicines Agency and operates in compliance with the Norwegian Animal Welfare Act. Alv B AS is authorized by the Norwegian Food Safety Authority (Mattilsynet) for conducting clinical trials in veterinary medicine (Approval No. MT-2023-0845). All research and development activities are conducted in accordance with Norwegian biotechnology regulations and international standards for comparative oncology research.

Alv B AS is a Norwegian biotech company that develops cutting-edge, cost-effective cancer treatments for dogs. We benefit from a forward-thinking team well-versed in the latest advances in cancer research on humans, as well as dogs.

Alv B AS Copyright 2025 © All Right Reserved.

Alv B AS is a registered company in Norway (Org.nr. 924 846 208). The company is authorized under the Norwegian Medicines Agency and operates in compliance with the Norwegian Animal Welfare Act. Alv B AS is authorized by the Norwegian Food Safety Authority (Mattilsynet) for conducting clinical trials in veterinary medicine (Approval No. MT-2023-0845). All research and development activities are conducted in accordance with Norwegian biotechnology regulations and international standards for comparative oncology research.

Alv B AS is a Norwegian biotech company that develops cutting-edge, cost-effective cancer treatments for dogs. We benefit from a forward-thinking team well-versed in the latest advances in cancer research on humans, as well as dogs.

Alv B AS Copyright 2025 © All Right Reserved.

Alv B AS is a registered company in Norway (Org.nr. 924 846 208). The company is authorized under the Norwegian Medicines Agency and operates in compliance with the Norwegian Animal Welfare Act. Alv B AS is authorized by the Norwegian Food Safety Authority (Mattilsynet) for conducting clinical trials in veterinary medicine (Approval No. MT-2023-0845). All research and development activities are conducted in accordance with Norwegian biotechnology regulations and international standards for comparative oncology research.